Lobe Sciences Ltd.

Lobe Sciences Ltd. (OTCQB:LOBEF CSE:LOBE) is proud to welcome Mr. Yong Yao, MBA, CGMA, FCMA, as Chief Financial Officer & Executive Vice President at Lobe Sciences, effective June 1, 2025. Mr. Yao is an experienced Chief Financial Officer and Pharmaceutical researcher and has operated in public and private environments for over 25 years. Join us in welcoming Mr. Yao to the Lobe Sciences team! #Leadership #Biotech #CFO #LobeSciences #RareDiseases #LifeSciences #CapitalMarkets #HealthcareInnovation  https://lnkd.in/gXZar_z6

We’re pleased to share an update from Lobe Sciences (CSE:LOBE, OTCQB:LOBEF): Cynaptec Pharmaceuticals, our new subsidiary now owned by Lobe and its private investors, has successfully raised $6M in funding to advance its development pipeline, including Conjugated Psilocin™. With a clear path toward preclinical and clinical studies, Cynaptec Pharmaceuticals is advancing treatments for significant medical needs especially chronic cluster headache, General Anxiety Disorder and Addiction. #Biopharma #Innovation #Healthcare

https://lnkd.in/gjmXyrPp

Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)

Launching a new product like Altemia ® Medical Food (MF) involves securing reimbursement pathways from insurers and other third-party payers. Unfortunately, the process for medical food lacks clear guidelines. Each state has its own rules, requiring separate applications for reimbursement approval in 2025. Meanwhile, we are collaborating with several Sickle Cell Disease (SCD) research clinics to gather additional data on the benefits of Altemia ® MF and its impact on this debilitating disease. 

Dr. Frederick D. Sancilio (CEO & Board Chairman) and Mr. Rick Goulburn (COO & Board Member) look forward to Day 2 of #2025SOT

The 505(b)(2) pathway is widely used by many applicants, if not most, for seeking market approval from the FDA. This pathway allows applicants to reference existing data from other companies that is pertinent to their product. For instance, with L-130, our new psilocin conjugate, we can leverage numerous high-quality publications that provide safety data for psilocybin or psilocin. By combining this existing data with our own research, we can build a compelling case for the safety of psilocin, regardless of the method of ingestion.  To readdress the question regarding Lobe's utilization of this pathway, we can confidently state that we plan to use this approach if we conclude that it will expedite approval. 

VANCOUVER, B.C. -- Lobe Sciences Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), (FWB: LOBE.F), a commercial stage biopharmaceutical company focused on developing products to treat unmet medical needs, today announced the appointment of Dr. Herman Williams as the Chief Executive Officer of Altemia, Inc. Altemia, Inc. is a wholly owned subsidiary of Lobe Sciences which is commercializing a unique medical food product to address the dietary needs of patients suffering from Sickle Cell Disease. Dr. Williams will be leading the launch of Altemia ®, in 2025 into select communities under the direct supervision of physicians who treat this genetic disorder. Dr. Williams is a highly seasoned healthcare executive with extensive experience including senior roles with large-scale hospitals and clinics, as Chief Clinical Officer for several companies, and as a founder of HW Healthcare Solutions in 2022. Dr. Williams is a recipient of numerous prestigious awards, including this past month the American Heart Association’s William T. Coakley award for his relentless commitment to its mission. Dr. Williams holds a Doctor of Medicine degree from Boston University School of Medicine, a Master’s of Business Administration from the University of Washington, and a Master’s in Public Health from Harvard University. “We are very excited that Dr. Williams is bringing his significant experience and commitment to the Lobe Sciences executive team. We are looking forward to the successful launch of Altemia ® Medical Food to support patients with Sickle Cell Disease” said Dr. Harry Jacobson, Chairman of Altemia, Inc.  

Dr. Fred D. Sancilio (CEO & Board Chairman) and Mr. Rick Goulburn (COO & Board Member) are attending the Society of Toxicology (SOT) Annual Meeting and ToxExpo in Orlando, FL next week. #2025SOT

L-130 is a conjugated form of psilocin, while CYB003 is a deuterated form of psilocin. Lobe has achieved something unique by stabilizing the active metabolite of psilocybin (a prodrug found in some mushrooms), which is psilocin. Psilocin is typically unstable and cannot be used as an active drug. By synthesizing dozens of combinations of psilocin with other materials, we discovered that combining psilocin with Mucic acid forms a stable new material. This salt of a weak acid and weak base is called Conjugated Psilocin (CP) or L-130. It has shown to be stable for over two years and can be used as a pharmaceutical ingredient. Additionally, it has demonstrated high bioavailability and safety in clinical trial with healthy volunteers. We have filed numerous patents to protect this novel material and two patents have been issued. CYB003 is a deuterated form of psilocin where certain hydrogen atoms are replaced with deuterium, a heavier isotope of hydrogen. Some claim that this form has enhanced stability, but the actual data supporting this has not been made public. Lobe now has a superior form of a highly active drug candidate and is developing it to treat several unmet medical needs, including those being investigated with CYB003, but without using isotopes, which are not typically used in the pharmaceutical industry as therapeutics.